

Fundraising




Tridek-One SAS is a leading biotech start-up specialized in the research and development of **CD31 agonists** to restore the immune balance

Objectives:

- Share the news of Tridek-One closing a €16M financing round to further identify development candidates against auto-immune diseases and conduct IND-enabling studies
- Introduce the new CEO, Laurence de Schoulepnikoff and Erik van den Berg as chairman of the board of directors
- As well as, further building the organisation and highlighting new and current investors

Strategy:

- Drafting the news release in French and English and issuing the news to international media, analysts and investors
- Share news via the ALA social media channels
- Follow up with key media targets organising interviews
 Results:
- The announcements gained a total of 46 articles, with coverage in leading publications
 Labiotech, Biotech Finances, BioCentury and Entrepreneur
- Arranged media briefings including an interview on Labiotech podcast Beyond Biotech
- Positive reception on ALA social media accounts





Nick Herbert and 41 others

4 comments - 3 reposts